Well, this is all we really need to take notice of....
“The discontinuation of the GSK trial has no impact on Immutep’s three other product candidates all of which have different mechanisms of action, including its lead product candidate eftilagimod alpha. In addition, there is no impact to Immutep’s funding capacity for the development of its in-house programs. The Company remains in a robust operational and financial position with a cash runway beyond the end of calendar year 2022” end
- Forums
- ASX - By Stock
- IMM
- Ann: Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
Ann: Ulcerative Colitis Phase II Study of GSK2831781 Discontinued, page-5
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
32.0¢ |
Change
0.020(6.67%) |
Mkt cap ! $464.8M |
Open | High | Low | Value | Volume |
30.5¢ | 32.3¢ | 30.0¢ | $1.040M | 3.328M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 31.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 42705 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.315 |
4 | 120476 | 0.310 |
4 | 137420 | 0.305 |
2 | 39246 | 0.295 |
4 | 20750 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 42705 | 2 |
0.325 | 27420 | 2 |
0.330 | 186564 | 5 |
0.335 | 33333 | 1 |
0.340 | 45281 | 5 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
NEWS
Is oil undervalued?
IMM (ASX) Chart |